Cargando…
Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging
The advent of Adcetris™ and Kadcyla™, two recently FDA-approved antibody–drug conjugates (ADCs), in the clinic has had a major impact on the treatment of lymphoma and breast cancer patients, respectively, worldwide. Despite these successes many new ADCs fail at various stages of development, often d...
Autores principales: | Schumacher, Felix F., Nunes, João P. M., Maruani, Antoine, Chudasama, Vijay, Smith, Mark E. B., Chester, Kerry A., Baker, James R., Caddick, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royal Society of Chemistry
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159697/ https://www.ncbi.nlm.nih.gov/pubmed/25103319 http://dx.doi.org/10.1039/c4ob01550a |
Ejemplares similares
-
Next-generation disulfide stapling: reduction and functional re-bridging all in one
por: Lee, Maximillian T. W., et al.
Publicado: (2016) -
In Situ Maleimide Bridging of Disulfides and a New Approach to Protein PEGylation
por: Schumacher, Felix F., et al.
Publicado: (2011) -
Homogeneous antibody fragment conjugation by disulfide bridging introduces ‘spinostics'
por: Schumacher, Felix F., et al.
Publicado: (2013) -
Acid-cleavable thiomaleamic acid linker for homogeneous antibody–drug conjugation
por: Castañeda, Lourdes, et al.
Publicado: (2013) -
Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering
por: Lee, Maximillian T. W., et al.
Publicado: (2017)